

7 April 2025

United States of America tariff update

SomnoMed Limited (ASX "SOM" or the Company), the leading provider of oral appliance treatment solutions for sleep-related breathing disorders and obstructive sleep apnea (OSA), provides an update in response to the reciprocal tariffs announced by the United States of America (USA) on 2 April 2025 US time.

SomnoMed has conducted a preliminary assessment of the potential impact of these new tariffs on goods imported into the USA, noting the Philippines is the primary manufacturing location for SomnoMed's products.

Given the uncertain and evolving impact of the USA tariff policies, SomnoMed will continue to evaluate how these tariffs affect our operations and adjust our response accordingly. In the immediate term, the Company plans to absorb the costs associated with the tariff changes. We remain committed to ensuring patients have uninterrupted access to care.

SomnoMed reiterates its previous FY25 guidance of approximately \$105 million revenue and EBITDA¹ of between \$7 million to \$9 million.

¹ EBITDA excludes AASB 16 lease payments, share/option expenses, unrealised foreign exchange gain/(loss), one off restructure costs and discontinued operations

---ends---

This release has been approved by the Board of SomnoMed Limited.

For further information please contact

Investor Relations: ir@somnomed.com

SomnoMed Limited - 20 Clarke St, Crows Nest, NSW, Australia 2065

About SomnoMed SomnoMed is a public company providing treatment solutions for sleep-related breathing disorders including obstructive sleep apnea, snoring and bruxism. SomnoMed was commercialised on the basis of extensive clinical research. Supporting independent clinical research, continuous innovation and instituting medical manufacturing standards has resulted in SomnoDent® becoming the state-of-the-art and clinically proven medical oral appliance therapy for more than 970,000 patients in over 20 countries. For additional information, visit SomnoMed at http://www.somnomed.com.au